STANDARD BIOTOOLS INC.

LAB

CIK 0001162194 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue

$24M

Gross Profit

$11M

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average

50/100

Profitability
0ROIC -21.1% (10% = solid, 20%+ = moat)
Liquidity
100Current Ratio 4.19 (above 1.5 = solid)
Leverage
100D/E 0.00 (under 0.5 = conservative)
Efficiency
0Asset Turnover 0.15x (1.0+ = capital-efficient)
Growth
0Insufficient data
Margin Trend
100Op Margin -168.5% · trend +6.7pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash

Capex (TTM)

$8M

investment in PP&E

Stock buybacks (TTM)

share count reduction

Stock-based comp (TTM)

$30M

non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot

Total assets

$568M

everything owned

Total liabilities

$143M

everything owed

Stockholders' equity

$424M

shareholder claim

Net debt

$-121M

Net cash position ($121M)

Recent performance · 63 quarters

Revenue

$24M

Net Income↓-28.8% -$8M

$-35M

Free Cash Flow↑+85.9% +$3M

$-476K

Operating Margin↓-47.6pts

-168.5%

Drill down

LAB Sankey

See STANDARD BIOTOOLS INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

LAB Charts

63 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

LAB Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics